We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Co-Diagnostics’ CoPrimers Platform Demonstrates Effectiveness in COVID-19 Saliva PCR Tests Without Sample Extraction

By LabMedica International staff writers
Posted on 12 Nov 2020
A new platform technology has shown to be effective in COVID-19 saliva PCR tests without sample extraction.

A recent whitepaper from Co-Diagnostics, Inc. More...
(Salt Lake City, UT, USA) has demonstrated that the company’s CoPrimer platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample, and can do so while providing low limits of detection. The technical advance featured in the whitepaper was the result of a study into the compatibility of CoPrimer technology with detection of SARS-CoV-2 directly from raw saliva. Various CoPrimer assay configurations were used to consistently detect SARS-CoV-2 in minimally processed saliva in the whitepaper, which concludes that CoPrimers provide a robust platform for the development of such tests.

The release of the company whitepaper follows recent news that Clinical Reference Laboratory (CRL) is now selling its CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers. The CRL announcement states that the test uses CoPrimer probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity, and a simple saliva collection device that can be administered in virtually any setting, with results in typically 24 hours that are delivered via a secure online computer or mobile device platform.

"The market for high-throughput, cost-effective COVID-19 tests continues to be strong, and eliminating the costly and time-consuming RNA extraction step allows for even greater speed and economic advantages," said Dwight Egan, CEO of Co-Diagnostics. "We believe the conclusions of this whitepaper speak to the strength, innovation, and flexibility of our CoPrimer platform not just as it relates to creating improved testing technology for COVID-19, but also additional possibilities to implement CoPrimers in various other diagnostic applications. Our next steps include incorporating extraction-free saliva direct tests into the Company product offerings, including those for COVID-19, so they can be available to our customer base world-wide."

"CRL has been an invaluable customer and partner in providing high-quality molecular diagnostic COVID-19 tests to individuals and organizations across the country, helping to facilitate the safe reopening of schools, business, and other organizations. We are pleased that its CRL Rapid Response test will now be even more widely available to consumers online," added Egan.

Related Links:
Co-Diagnostics, Inc.


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.